Toggle Main Menu Toggle Search

Open Access padlockePrints

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

Lookup NU author(s): Professor Anthony De SoyzaORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Introduction: Non-cystic fibrosis bronchiectasis (NCFB) is an increasingly prevalent chronic respiratory disease, characterized by a cycle of infection and inflammation. It is progressive and associated with poor quality of life, increasing healthcare costs and mortality. Inhaled antibiotics offer the potential to decrease long-term bacterial burden and reduce or delay exacerbations which are a key driver of disease progression and healthcare costs. Currently however, no inhaled treatments are approved for the prevention of exacerbations in patients with NCFB.Areas covered: We consider current evidence for inhaled treatment in NCFB and discuss ciprofloxacin dry powder for inhalation (DPI), a novel treatment using PulmoSphere technology, delivered via a pocket-sized, breath-actuated inhaler. We also detail the unique features of the ongoing Phase 3 RESPIRE trials for ciprofloxacin DPI.Expert opinion: The simplicity of use and short administration time could make ciprofloxacin DPI an attractive treatment option with potential to reduce the number of exacerbations in patients with NCFB. The RESPIRE studies are the largest carried out in NCFB to date and will provide a benchmark for future trial design. If approved, following successful Phase 3 data, ciprofloxacin DPI has potential for significant use in NCFB due to its good tolerability and low treatment burden.

Publication metadata

Author(s): De Soyza A, Aksamit T

Publication type: Article

Publication status: Published

Journal: Expert Opinion on Orphan Drugs

Year: 2016

Volume: 4

Issue: 8

Pages: 875-884

Online publication date: 07/06/2016

Acceptance date: 27/05/2016

ISSN (electronic): 2167-8707

Publisher: Taylor & Francis


DOI: 10.1080/21678707.2016.1196129


Altmetrics provided by Altmetric